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Dhe National Heart, Lung, and Blood Institute (NHLBI) is
ommitted to its public health mission of deepening under-
tanding of the pathobiology of cardiovascular (CV), lung,
nd blood disorders and translating this knowledge into
mproved care and clinical outcomes for patients and im-
roved public health. The Institute’s blueprint for guiding,
timulating, and supporting outstanding science in further-
nce of this mission is articulated in its Strategic Plan,
haping the Future of Research (http://apps.nhlbi.nih.gov/
trategicplan/). In the coming months, we plan to share
ith the JACC readership the NHLBI’s strategic vision in
V disease and its prevention, provide details of current and
eveloping programs designed to fulfill this vision, and
iscuss opportunities and challenges that are expected to
nfluence CV research in the years ahead. In making
rogrammatic decisions, we at the NHLBI rely tremen-
ously on discussions with the scientific, clinical, and public
ealth communities, and these communications with JACC
eaders will be designed to further stimulate such discourse.
The NHLBI carries out its mission through the support
f CV investigators, research trainees, and research pro-
rams nationwide. While we sustain a modest intramural
esearch effort, the vast majority of our CV research funds
re funneled directly to the extramural community through
ur Division of Cardiovascular Diseases and Division of
revention and Population Sciences. And the lion’s share of
hese extramural funds—66.0% to 71.2% during the past 10
ears—supports so-called investigator-initiated research,
amely, projects proposed and implemented by independent
nvestigators. The remainder is used for Institute-solicited
rom the National Heart, Lung, and Blood Institute, National Institutes of Health,
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arge-scale clinical trials, and epidemiologic studies) and
esearch training. During lean times as are occurring today,
he NHLBI places the highest emphasis on preserving
nvestigator-initiated research and nurturing trainees and
arly-stage investigators, so as to avoid gaps in the “pipeline”
f researchers that could jeopardize CV research efforts for
ecades to come.
The NHLBI Strategic Plan highlights the need for 2
tages of translation—moving basic knowledge into clinical
vidence and moving clinical evidence into clinical practice
nd public policy. Our long history of innovation in facili-
ating the first of these critical translational steps is exem-
lified by our support of specialized centers of clinically
riented research in a number of carefully defined topic
reas. The achievements of these centers have been signif-
cant; nonetheless, we continue to seek new, even more
roductive approaches to facilitate basic-to-clinical transla-
ion. Efforts toward the second translation step are being
pearheaded by our Division for the Application of Re-
earch Discoveries, which is on the threshold of launching
ntegrated evidence-based CV risk reduction guidelines for
hildren and adults and implementing programs to address
he growing problems of childhood obesity and health
isparities.
We are privileged to be leading NHLBI efforts during a
eriod of unprecedented technologic advances that promise
o facilitate extraordinary progress in CV diagnosis, treat-
ent, and prevention. In recent years, the NHLBI has
unded programs to accelerate development and application
f enabling technologies such as genomics, proteomics,
issue engineering, nanotechnology, and informatics. These
rograms will drive development of powerful new diagnostic
ools, advanced therapeutic approaches such as cell- and
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March 24, 2009:1082–3 CV Programs of the NHLBIene-based treatments, and far more personalized ap-
roaches to CV prevention and therapeutics.
Large-scale clinical trials funded by the NHLBI during
he past several decades have contributed enormously to the
ard evidence available to guide clinicians in the prevention
nd treatment of ischemic heart disease, heart failure, and
udden cardiac death. Evidence-based contributions to
anaging risk factors such as hyperlipidemia, hypertension,
nd diabetes mellitus have played a key role in the decline in
.S. CV mortality rates. NHLBI-supported clinical re-
earch efforts will continue to be directed toward exploring
oth efficacy of new treatments and effectiveness of already
vailable treatment strategies. Many of the insights behind
igorous intervention trials come from observations made in
ur landmark longitudinal cohort studies. These programs,
xemplified by the 60-year old Framingham Heart Study,
ave entered a new era of broadly exploring genotype–
henotype associations that will radically expand our under-
tanding of individual clinical risk and the underlying
enetic basis of CV diseases. Importantly, the primary
nformation derived from these programs is now being
penly shared with the scientific community as a challenge
o all investigators to help translate these efforts into
cientific and clinical gain. We are transforming ourselves
nto a laboratory for exploring clinical investigational meth-
dologies; the insights that emerge can be expected to
apidly and efficiently inform future evidence-based medical
ractice.On a final note, let us mention
he Institute’s growing involve-
ent in the worldwide epidemic
f CV disease. Cardiovascular dis-
ase accounts for 30% of global
eaths, 65% of which occur in the
eveloping world. The reality that
0% of premature CV deaths are preventable constitutes an
rgent call to action. Our recently announced program in
lobal CV health will help drive a far-reaching CV disease
revention effort and, at the same time, advance our
ophistication in preventive strategies that can then be
eapplied in our own nation of disparate health care delivery
nd outcomes.
In a series of articles to appear in JACC, we will expand
ur discussion of many of these areas and programs. We are
onfident that these communications will not only inform
he clinical community about the NHLBI’s activities, but
lso enrich the dialogue needed to help us better serve our
ission of advancing the CV health of our nation and our
orld.
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Abbreviations
and Acronyms
CV  cardiovascular disease
NHLBI  National Heart,
Lung, and Blood Institute
